Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Apr 24th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period.</li>
<li>We highlight short changes in Hua Hong Semiconductor, Kuaishou, CCB, ICBC, Techtronic, Zijin Gold Intl, BYD.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Apr 24th.
Top short increases and decreases were tabulated for one week and four week period.
We highlight short changes in Hua Hong Semiconductor, Kuaishou, CCB, ICBC, Techtronic, Zijin Gold Intl, BYD.


HK Short Interest Weekly: Hua Hong Semiconductor, Kuaishou, CCB, ICBC, Techtronic, Zijin Gold Intl

HK/China Equity Long-Short

Osbert Tang, CFA

Equity Capital Markets

Star Sports Medicine / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/star-sports-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:45717:1" rel="noopener">Star Sports Medicine (1609 HK)</a> is in an excellent position to gain market share from the overseas players in China, given its increased popularity among hospitals.</li>
<li>The company is expected to achieve an EPS CAGR of 21.5% between FY25 and FY28F, fueled by revenue growth and a steady expansion in gross margin.</li>
<li>Its IPO is priced at 20.1x FY26F PER. By attributing a 20% premium over the global average, it equals a fair price of HK$106.7, an upside of 8%.</li>
</ul>



Star Sports Medicine (1609 HK) is in an excellent position to gain market share from the overseas players in China, given its increased popularity among hospitals.
The company is expected to achieve an EPS CAGR of 21.5% between FY25 and FY28F, fueled by revenue growth and a steady expansion in gross margin.
Its IPO is priced at 20.1x FY26F PER. By attributing a 20% premium over the global average, it equals a fair price of HK$106.7, an upside of 8%.


Star Sports Medicine (1609 HK) IPO: Possibly Some Upside

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Apr 17th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period.</li>
<li>We highlight short changes in Pop Mart Intl, Alibaba, Akeso, 3Sbio, China Life, Zijin Gold Intl, Guotai Junan I.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Apr 17th.
Top short increases and decreases were tabulated for one week and four week period.
We highlight short changes in Pop Mart Intl, Alibaba, Akeso, 3Sbio, China Life, Zijin Gold Intl, Guotai Junan I.


HK Short Interest Weekly: Pop Mart Intl, Alibaba, Akeso, 3Sbio, China Life, Zijin Gold Intl

Equity Derivatives and Volatility Specialist, Clifton Derivatives

John Ley

Equity Derivatives and Volatility Specialist

Clifton Derivatives

Independent derivative and volatility research firm focusing on events/catalysts, earnings, relative value and cross asset volatility strategies.

Equity Derivatives

<ul>
<li>A softer headline week, with Friday strength and supportive overseas markets setting up renewed strength on Monday.</li>
<li>Breadth was mixed, with gainers fewer in impact than decliners as downside moves remained more pronounced.</li>
<li>Implied vols continued to ease, pushing index and single stock percentiles materially lower.</li>
</ul>


A softer headline week, with Friday strength and supportive overseas markets setting up renewed strength on Monday.
Breadth was mixed, with gainers fewer in impact than decliners as downside moves remained more pronounced.
Implied vols continued to ease, pushing index and single stock percentiles materially lower.


Hong Kong Single Stock Options Weekly (April 20–24): Friday Rebound and Falling Vols Offer Support

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Mar 27th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period.</li>
<li>We highlight short changes in YOFC, Pop Mart Intl, China Hongqiao, AIA, Bidu, Zijin Gold International, Cmoc, Zhejiang Leapmotor Technology.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Mar 27th.
Top short increases and decreases were tabulated for one week and four week period.
We highlight short changes in YOFC, Pop Mart Intl, China Hongqiao, AIA, Bidu, Zijin Gold International, Cmoc, Zhejiang Leapmotor Technology.


HK Short Interest Weekly: YOFC, Pop Mart Intl, China Hongqiao, AIA, Bidu, Zijin Gold International

China

Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Akeso (9926 HK)

HK Short Interest Weekly: Hua Hong Semiconductor, Kuaishou, CCB, ICBC, Techtronic, Zijin Gold Intl

We analyzed the latest HK SFC report for aggregate short position as of Apr 24th and highlight short interest changes in Hua Hong Semiconductor,...

Ke Yan, CFA, FRM

Star Sports Medicine (1609 HK) IPO: Possibly Some Upside

Star Sports Medicine is poised to capture market share in China with growing hospital popularity, a projected 3-year EPS CAGR of 21.5%, IPO priced...

Osbert Tang, CFA

HK Short Interest Weekly: Pop Mart Intl, Alibaba, Akeso, 3Sbio, China Life, Zijin Gold Intl

We analyzed the latest HK SFC report for aggregate short position as of Apr 17th and highlight short interest changes in Pop Mart Intl, Alibaba,...

Ke Yan, CFA, FRM

Hong Kong Single Stock Options Weekly (April 20–24): Friday Rebound and Falling Vols Offer Support

HSI ended lower on the week, but Friday strength and easing implied vols suggest a more supportive near-term backdrop which should get a boost from...

John Ley

HK Short Interest Weekly: YOFC, Pop Mart Intl, China Hongqiao, AIA, Bidu, Zijin Gold International

We analyzed the latest HK SFC report for aggregate short position as of Mar 27 and highlight short interest changes in YOFC (6869 HK), Pop Mart...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

HK Short Interest Weekly: Hua Hong Semiconductor, Kuaishou, CCB, ICBC, Techtronic, Zijin Gold Intl

We analyzed the latest HK SFC report for aggregate short position as of Apr 24th and highlight short interest changes in Hua Hong Semiconductor,...

Ke Yan, CFA, FRM

Star Sports Medicine (1609 HK) IPO: Possibly Some Upside

​Star Sports Medicine is poised to capture market share in China with growing hospital popularity, a projected 3-year EPS CAGR of 21.5%, IPO priced...

Osbert Tang, CFA

HK Short Interest Weekly: Pop Mart Intl, Alibaba, Akeso, 3Sbio, China Life, Zijin Gold Intl

We analyzed the latest HK SFC report for aggregate short position as of Apr 17th and highlight short interest changes in Pop Mart Intl, Alibaba,...

Ke Yan, CFA, FRM

Hong Kong Single Stock Options Weekly (April 20–24): Friday Rebound and Falling Vols Offer Support

HSI ended lower on the week, but Friday strength and easing implied vols suggest a more supportive near-term backdrop which should get a boost from...

John Ley

HK Short Interest Weekly: YOFC, Pop Mart Intl, China Hongqiao, AIA, Bidu, Zijin Gold International

We analyzed the latest HK SFC report for aggregate short position as of Mar 27 and highlight short interest changes in YOFC (6869 HK), Pop Mart...

Ke Yan, CFA, FRM

Star Sports Medicine is poised to capture market share in China with growing hospital popularity, a projected 3-year EPS CAGR of 21.5%, IPO priced...